您现在的位置: 生物谷 > 生物制药 > 新药研发 > 正文

GSK启动抗疟疾药物tafenoquine III期全球项目

2014年5月1日讯 /生物谷BIOON/ --葛兰素史克(GSK)和非营利组织“抗疟药品事业会”(Medicines for Malaria Venture,MMV)4月29日宣布,启动一项III期全球项目,评估他非诺喹(tafenoquine)用于间日疟(Plasmodium vivax malaria,P. vivax)治疗及预防复发(根治)的疗效和安全性。FDA于2013年12月授予tafenoquine突破性疗法认定,目前该药尚未获任何监管批准。

间日疟(P.vivax malaria)是一种被忽视热带病(neglected tropical disease,NTD),同时也是导致无并发症疟疾(uncomplicated malaria)的主要病因。间日疟对公共健康和经济有显著影响,主要是在南亚、东南亚、拉丁美洲和非洲,在这些地区,估计每年有7000万-3.9亿临床病例发生。

该III期项目包括2个随机、双盲治疗研究:DETECTIVE(TAF112582)研究旨在调查tafenoquine与氯喹(chloroquine)联合用于间日疟成人患者的疗效、安全性和耐受性。氯喹(chloroquine)是一种血液阶段抗疟疾药物。GATHER(TAF116564)研究旨在评估tafenoquine用于间日疟根治时相对于伯氨喹(primaquine)的溶血发生率、安全性和疗效。伯氨喹(primaquine)是目前唯一获批用于间日疟根治的药物。

关于Tafenoquine:

tafenoquine是一种实验性9-氨基喹啉衍生物,具有抗间日疟(P.vivax)生命周期的活性,包括位于肝脏中的休眠形式的间日疟原虫。沃尔特·里德陆军研究所(Walter Reed Army Institute of Research)的科学家于1978年首次发现tafenoquine,该药目前正由GSK正与MMV联合开发。(生物谷Bioon.com)

英文原文:GSK and MMV announce start of phase III programme of tafenoquine for Plasmodium vivax malaria

Issued: Monday 29 April 2014, London UK

GlaxoSmithKline (GSK) and Medicines for Malaria Venture (MMV) today announced the start of a phase III global programme to evaluate the efficacy and safety of tafenoquine, an investigational medicine which is being developed for the treatment and relapse prevention (radical cure) of Plasmodium vivax (P. vivax) malaria.

P. vivax malaria, a form of the disease caused by one of several species of Plasmodium parasites known to infect humans, occurs primarily in South and South East Asia, Latin America and the horn of Africa. Severe anaemia, malnutrition and respiratory distress are among the most serious consequences described to be caused by the infection.

The phase III programme includes two randomised, double-blind treatment studies to investigate tafenoquine in adult patients with P. vivax malaria. The “DETECTIVE” study (TAF112582) aims to evaluate the efficacy, safety and tolerability of tafenoquine as a radical cure for P. vivax malaria, co-administered with chloroquine, a blood stage anti-malarial treatment. The “GATHER” study (TAF116564) aims to assess the incidence of hemolysis and safety and efficacy of tafenoquine compared to primaquine, the only approved treatment currently available for the radical cure of P. vivax malaria.

Tafenoquine is not yet approved or licensed for use anywhere in the world.

“P. vivax malaria can affect people of all ages and is particularly insidious because it has the potential to remain dormant within the body in excess of a year, and causes some patients to experience repeated episodes of illness after the first mosquito bite,” said Nicholas Cammack, Head, Tres Cantos Medicines Development Centre for Diseases of the Developing World.  “Our investigation of tafenoquine for the treatment of P. vivax malaria is part of GSK’s efforts to tackle the global burden of malaria. Working with our partners, including MMV, we are determined to stop malaria in all its forms.” 

 “One of the big challenges we face in tackling malaria is to have new medicines to prevent relapse, caused by dormant forms of P. vivax, said Dr Timothy Wells, MMV’s Chief Scientific Officer. “The phase III programme is designed to build upon the promising results of the phase IIb study which showed that treatment with tafenoquine prevented relapses. If successful, tafenoquine has the potential to become a major contributor to malaria elimination.1 It’s a great privilege to be working with GSK on this project; they have a clear commitment to changing the face of public health in the countries in which we are working.”

About P. vivax malaria

P. vivax malaria is a neglected tropical disease and a major cause of uncomplicated acute malaria. It has a significant public health and economic impact primarily in South and South East Asia, Latin America and the horn of Africa, where the majority of the estimated 70-390 million annual clinical cases occur. The P. vivax parasite causes relapses from a dormant liver form established immediately after an infected mosquito bite. This dormant form leads to the reappearance of clinical malaria anywhere between a few weeks to several months, and sometimes in excess of a year, after the initial infection.

About Tafenoquine

Tafenoquine is an investigational 8-aminoquinoline derivative with activity against the P. vivax lifecycle, including the form that lies dormant in the liver. Tafenoquine was first discovered by scientists at the Walter Reed Army Institute of Research in 1978 and is being developed in collaboration with GSK and MMV. The clinical programme investigates a single dose of tafenoquine, as part of a 3-day treatment course with chloroquine, in patients with P. vivax malaria.

Tafenoquine was granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) in December 2013. Breakthrough Therapy designation is the newest of the FDA’s programmes aimed at accelerating the development and review times of drugs for serious or life-threatening conditions.

关键词:抗疟疾药物,葛兰素史克,被忽视热带病,间日疟,tafenoquine

信息来源:生物谷